Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is nut carcinoma?
NUT carcinoma (also called NUT midline carcinoma) is a rare and aggressive cancer that is defined not by where it starts but by a specific genetic change inside the tumor cells. In these cancers, a gene called NUTM1 becomes abnormally fused to a partner gene — most often BRD4. This single fusion drives the cancer to grow quickly and keeps its cells in an immature, rapidly dividing state. NUT carcinoma can arise anywhere but most commonly appears along the midline of the body: the chest (around the lungs and the space between them), the head and neck, and the sinuses. Because it is rare and can look like other 'poorly differentiated' cancers under the microscope, it is often missed unless a pathologist specifically tests for the NUT protein. Confirming the diagnosis matters, because it explains the aggressive behavior and opens the door to clinical trials of drugs aimed directly at the fusion.
The main types
Doctors group nut carcinoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Thoracic (chest) NUT carcinoma | Arises in the lungs or the space between them (mediastinum). This is one of the most common locations and often presents with a large chest mass. |
| Head and neck / sinonasal NUT carcinoma | Starts in the sinuses, nasal cavity, or other head-and-neck sites. It can be mistaken for other sinus cancers until NUT testing is done. |
| Other / extra-midline sites | Less commonly, NUT carcinoma appears in other organs. Wherever it starts, the defining feature is the NUTM1 gene fusion, not the location. |
Staging, in plain terms
There is no NUT-carcinoma-specific staging system. Doctors use the standard TNM staging for the body site where the tumor started (for example, lung or sinonasal staging) — describing the size and reach of the tumor (T), spread to lymph nodes (N), and spread to distant organs (M). In practice, the most important distinction is whether the cancer is still confined to one area (where aggressive local treatment with surgery and radiation may be possible) or has already spread, since NUT carcinoma tends to grow and spread quickly.
| Site-based TNM + presence of distant spread | What it generally means |
|---|---|
| Localized | The cancer is confined to where it started, without distant spread. Treatment combines surgery when possible, radiation, and chemotherapy to control the disease as aggressively as possible. |
| Regionally advanced | The tumor is large or has reached nearby lymph nodes. Treatment uses combined chemotherapy and radiation, sometimes with surgery, and strong consideration of a clinical trial. |
| Metastatic | The cancer has spread to distant organs. Care focuses on systemic treatment (chemotherapy, targeted drugs in trials, sometimes immunotherapy) plus radiation to relieve symptoms, with clinical-trial enrollment strongly encouraged. |
The standard of care
NUT Carcinoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Multidisciplinary, aggressive combined treatment
Because NUT carcinoma is rare and fast-growing, the best results come from a coordinated team plan that often combines surgery (when the tumor can be removed), radiation, and chemotherapy started promptly.
Surgery (when feasible)
If the tumor is in a place where it can be safely removed and has not spread, surgery is used to take out as much cancer as possible, usually followed by radiation and chemotherapy.
Radiation therapy
High-dose radiation is a central tool for local control — given after surgery, combined with chemotherapy when surgery is not possible, and to relieve symptoms in advanced disease.
Chemotherapy
Chemotherapy is used to attack the cancer throughout the body. It can shrink tumors at first, but responses are often short-lived, which is why trials of targeted drugs are so important.
Targeted therapy and clinical trials
Drugs called BET inhibitors (such as the investigational agent ZEN-3694, which received FDA Fast Track and Orphan Drug designation in 2025) are designed to block the fusion protein. International guidelines strongly recommend enrolling in clinical trials whenever possible.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide and grow. NUT carcinoma cells divide very quickly, which can make them sensitive to radiation, so high-dose radiation is an important part of controlling the disease where it started — after surgery, in place of surgery when the tumor can't be removed, and to relieve symptoms such as pain or breathing problems in advanced disease. Modern techniques like intensity-modulated radiation and, for head-and-neck tumors, proton therapy shape the dose tightly around the cancer while protecting nearby organs. Radiation is painless during delivery, given over a series of daily sessions, and external-beam radiation leaves no radioactivity in the body. Because NUT carcinoma is aggressive, radiation is almost always combined with chemotherapy and, when possible, surgery rather than used alone.
The main ways radiation is delivered for nut carcinoma:
Intensity-modulated radiation (IMRT)
Beams are shaped precisely around the tumor to deliver a high dose while sparing nearby vital structures such as the lungs, heart, eyes, optic nerves, and brain, depending on the site.
Proton therapy (selected sites)
For sinus and head-and-neck tumors near the eyes and brain, protons can reduce dose to those sensitive structures and lower side effects.
Concurrent chemoradiation
Radiation and chemotherapy are given together so the chemotherapy makes the cancer cells more sensitive to radiation while also treating disease elsewhere in the body.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
International guidelines for diagnosis and treatment: An international expert group published consensus guidance in 2025 emphasizing prompt NUT testing, multidisciplinary care combining surgery, radiation, and chemotherapy, and prioritizing clinical-trial enrollment given the limited benefit of standard chemotherapy.[1]
The Innovation, International guidelines on the diagnosis and treatment of NUT carcinoma (2025)
Next-generation BET inhibitors: BET inhibitors target the fusion protein that drives NUT carcinoma. The investigational agent ZEN-3694 received FDA Fast Track and Orphan Drug designation in late 2025 and is being studied in combination with other targeted drugs for unresectable or metastatic disease.[2]
FDA designations and CancerNetwork reporting (2025)
Adding immunotherapy to first-line treatment: Researchers are studying whether adding immune checkpoint inhibitors to chemotherapy improves outcomes, with some patients showing meaningful and durable responses, supporting further trials.[3]
npj Precision Oncology and related case series (2024–2025)
Common questions
Why is testing for the NUT protein so important? NUT carcinoma can look like many other 'poorly differentiated' cancers under the microscope, so it is often missed unless the pathologist specifically tests for the NUT protein. Confirming the diagnosis explains the aggressive behavior, prevents misdiagnosis, and — critically — opens the door to clinical trials of drugs that target the fusion directly.
Is there a standard treatment? There is no single standard protocol because NUT carcinoma is so rare. The best approach is aggressive, coordinated care that often combines surgery (when possible), radiation, and chemotherapy, started quickly, with strong encouragement to join a clinical trial testing targeted drugs.
What are BET inhibitors? BET inhibitors are targeted drugs designed to block the very protein the NUTM1 fusion produces, which the cancer depends on to grow. Several are being tested in trials, and newer ones such as ZEN-3694 have received FDA designations to speed their study. They are not yet a routine approved treatment, which is why trial enrollment matters.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- The Innovation, International guidelines on the diagnosis and treatment of NUT carcinoma (2025) (no indexed identifier — see your care team) ↩
- FDA designations and CancerNetwork reporting (2025) (no indexed identifier — see your care team) ↩
- npj Precision Oncology and related case series (2024–2025) (no indexed identifier — see your care team) ↩